Blood Coagulation Testing Market size was over USD 4.9 billion in 2024 and is estimated to reach USD 9.3 billion by the end of 2037, expanding at a CAGR of 5.5% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of blood coagulation testing is evaluated at USD 5.1 billion.
The increasing prevalence of coagulation-related disorders such as hemophilia, thrombophilia, and vitamin K deficiency is significantly boosting the demand for reliable and efficient blood coagulation tests. According to a report by the CDC in May 2024, each year up to 900,000 people in the U.S. are affected by venous thromboembolism (VTE), which is a type of blood clot. These conditions require precise monitoring and early detection to prevent complications, driving the adoption of advanced diagnostic solutions. The growing awareness among patients and healthcare providers about the importance of accurate testing further supports market expansion, emphasizing the need for innovative technologies to enhance testing accuracy and efficiency.
Additionally, the global increase in the elderly population, who are more susceptible to coagulation-related disorders such as deep vein thrombosis and atrial fibrillation, is driving blood coagulation market growth. As per a study published in Springer Nature in July 2024, a study of 1,148 older patients in long-term care hospitals found a high lifetime prevalence (9.6%) and incidence of venous thromboembolism (2.82 per 100 person-years). Older adults often require frequent monitoring to manage these conditions effectively, leading to a higher demand for blood coagulation tests. This trend is further supported by the rising focus on preventive healthcare and advancements in diagnostic technologies, ensuring better detection and management of coagulation disorders in aging populations.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
5.5% |
|
Base Year Market Size (2024) |
USD 4.9 billion |
|
Forecast Year Market Size (2037) |
USD 9.3 billion |
|
Regional Scope |
|
Product (Analyzer, Consumables)
The consumables segment is likely to hold blood coagulation testing market share of more than 63.2% by 2037. The segment’s growth is attributed to the rising frequency of diagnostic procedures for conditions such as hemophilia and thrombosis. Consumables such as reagents, test strips, and controls are essential for daily testing, ensuring consistent demand. Additionally, the increasing adoption of point-of-care testing and automated systems has boosted the need for consumables compatible with these technologies. For instance, in June 2023, Sysmex launched an antimicrobial susceptibility testing system that improved diagnostic efficiency, highlighting advancements that also benefit the blood coagulation testing market.
End use (Hospitals, Research Institutes, Diagnostic Centers)
By end use, the hospital segment is estimated to garner the majority of market revenue over the forecast period. The segment is growing due to the increasing prevalence of coagulation disorders such as hemophilia, thrombosis, and stroke. Hospitals are the primary centers for diagnosis and treatment, equipped with advanced diagnostic tools and skilled professionals for comprehensive testing. The rising number of inpatient admissions requiring coagulation monitoring and the availability of specialized care in hospitals further boost demand. Additionally, growing healthcare infrastructure investments enhance hospitals' testing capabilities, driving segment growth.
Our in-depth analysis of the global blood coagulation testing market includes the following segments:
|
Product |
|
|
End use |
|
|
Test |
|
|
Technology |
|
North America Market Statistics
North America in blood coagulation testing market is poised to capture over 45.5% revenue share by 2037. The rising prevalence of coagulation disorders, such as hemophilia, thrombophilia, and vitamin K deficiency, is driving the demand for accurate and efficient blood coagulation tests. Additionally, the introduction of innovative technologies, including automated analyzers and molecular diagnostics, has significantly improved testing efficiency and accuracy. These advancements enable faster, more precise diagnosis and are fueling the blood coagulation testing market growth by meeting the increasing demand for effective coagulation disorder management and enhancing patient outcomes.
The growing aging population in the U.S. is leading to a higher incidence of coagulation-related disorders such as stroke and thrombosis, increasing the demand for blood coagulation tests. Older adults require consistent monitoring for blood clotting issues, further driving the blood coagulation testing market growth. Additionally, increased government funding for healthcare infrastructure and research is facilitating advancements in coagulation testing technologies. According to the American Medical Association, health spending in the U.S. rose by 4.1% in 2022, reaching USD 4.5 trillion, or USD 13,493 per person. Investments enhance innovative technologies, improving healthcare availability and outcomes.
The government of Canada increased healthcare investments have enhanced access to advanced diagnostic tools, improving the availability and accuracy of blood coagulation tests. According to a July 2024 Government of Canada report, the government spent about USD 200 billion over ten years to enhance healthcare services. Alongside this, the development and adoption of innovative testing technologies, such as automated analyzers and molecular diagnostics, have further boosted test efficiency and precision. These combined factors are driving the blood coagulation testing market growth by making coagulation tests more accessible, efficient, and accurate, ensuring better management of coagulation-related disorders in Canada.
Asia Pacific Market Analysis
In APAC the blood coagulation testing market is poised to garner a lucrative market share over the forecast period. Countries such as China and India are investing heavily in healthcare infrastructure, adopting advanced diagnostic tools that enhance access to blood coagulation testing services. This expansion, supported by government funding for healthcare development across Asia Pacific, is driving the blood coagulation testing market growth. The promotion of diagnostic tools and treatments of blood disorders ensures improved accessibility and affordability of tests, which in turn fuels the demand for accurate and efficient blood coagulation testing, contributing to market expansion in the region.
The aging population in China is leading to a rise in coagulation-related health issues such as stroke and thrombosis, driving demand for blood coagulation testing. According to an NLM report of January 2024, between 2011 and 2019, THA cases in China increased from 168,040 to 577,153. Additionally, increasing awareness about coagulation disorders, along with improved healthcare access in both urban and rural areas, is further fueling the need for coagulation testing services. These factors are collectively contributing to the growth of the blood coagulation testing market in China, expanding both the demand and availability of diagnostic services.
The adoption of automated analyzers and molecular diagnostic technologies in India is enhancing the accuracy and efficiency of blood coagulation testing, contributing to market growth. Additionally, the government of India invests in healthcare infrastructure and public health programs improving access to advanced diagnostic tools, further boosting the availability of blood coagulation testing services. In March 2023, the Journal of Medical Sciences mentioned that the country's hospital sector, which makes up 80% of the healthcare system overall was estimated to value USD 132 billion in 2023. These combined efforts are driving the overall market expansion of the blood coagulation testing in India.
Key companies are innovating the blood coagulation testing market by developing advanced technologies such as automated blood coagulation analyzers, chemiluminescence enzyme immunoassay (CLEIA), and molecular marker-based testing. These innovations improve diagnostic accuracy, efficiency, and speed, allowing for faster detection of coagulation abnormalities. For instance, in May 2022, HORIBA Medical showcased its latest Yumizen G hemostasis analyzers and reagents at ISTH 2022, enhancing laboratory productivity and efficiency. Additionally, integrating these technologies into single devices enables comprehensive testing, driving market growth by enhancing the capabilities of healthcare providers to manage and treat coagulation disorders more effectively. Some of these players are:
Author Credits: Radhika Pawar
Copyright © 2025 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?